【Yung Shin】February 2026 Monthly Revenue NT$524 Million (YoY -16.7%)
NQ Score
50/100
N1 Content Completeness
4
AI Summary (NQ-processed)
Taiwan's major pharmaceutical manufacturer, Yung Shin (3705), announced its financial data for February 2026. The company's monthly revenue was NT$524 million, a 16.7% decrease compared to the same period last year. This decline may be related to seasonal factors in pharmaceutical sales or adjustments in national health insurance drug pricing policies, reflecting the operational challenges within the pharmaceutical industry.
AI analysis data is not yet available.
Frequently Asked Questions
- Q: What was Yung Shin's total revenue for February 2026?
- A: Yung Shin's total revenue for February 2026 was NT$523,507 thousand, which is approximately NT$524 million.
- Q: How did Yung Shin's February 2026 revenue compare to the previous year?
- A: Yung Shin's revenue in February 2026 experienced a year-over-year decrease of 16.7%.
- Q: What is the company code for Yung Shin?
- A: The company code for Yung Shin is 3705.
- Q: In which industry sector does Yung Shin operate?
- A: Yung Shin operates within the Biotechnology and Medical industry sector.
- Q: What was the specific monthly revenue figure reported for February 2026 by Yung Shin?
- A: The specific monthly revenue figure reported by Yung Shin for February 2026 was NT$523,507 thousand.